INTC Research Update — September 20, 2026 (Updated)
Updated Thesis
Intel designs and manufactures CPUs, GPUs, networking silicon, and edge and data-center products across its Client Computing, Data Center and AI, and Intel Foundry segments, employing roughly 85,100 people under CEO Lip-Bu Tan. The business quality is currently low: TTM gross margin is 38.9%, TTM operating margin is 0.1%, TTM net margin is -19.8%, and ROE is -10.8%, so the company is not earning an economic return on capital, and earnings fell 278.1% year over year in the most recent quarter even as revenue grew 25.4% year over year in that same quarter. The shares are expensive on every cash-based measure, with P/S of 11.27, P/FCF of 229.67, and EV/EBITDA of 185.24, and the stock trades at $127.39 against a $116.75 fair value estimate, implying 8.4% downside to fair value, or a 9.1% premium to fair value.
The investment grade as of this refresh is D — solid business quality. Low-tier business, very expensive valuation, with 8.4% downside to $116.75 fair value.
Key Metrics at a Glance
- Revenue growth: +25.4% year over year
- Net margin: -19.8%
- Fair value upside: -8.4% to our estimate of $117
Current price: $127.39
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Intel Corp. remains in our covered universe with a solid-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full INTC research →](/stocks/INTC)